FardetL, DupuyA, KerobDet al.Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol, 2007; 56:624–628.
2.
ShahN. Hidradenitis suppurativa: A treatment challenge. Am Fam Physician, 2005; 72:1547–1552.
3.
PapadopoulosAJ, KihiczakG, SchwartzRA. Hidradenitis suppurativa. An update. Acta Dermatovenerol Alp Panonica Adriat, 2000; 9:xx–xx.
4.
PadbergJ, SchormannD, GrobuschM, BergmannF. Drug interaction of isotretinoin and protease inhibitors: Support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy. AIDS, 1999; 13:284–285.
5.
KhambhatiR, SinghalP, MarfatiaYS. Hidradenitis suppurativa in AIDS. Indian J Sex Transm Dis[serial online]2010[cited 2011 May 6]31:45–46.
6.
UnachukwuCN, UchennaDI, YoungEE. Endocrine and metabolic disorders associated with human immune deficiency virus infection. West Afr J Med, 2009; 28:3–9.
7.
MayoJ, CollazosJ, MartínezE, IbarraS. Adrenal function in the human immunodeficiency virus–infected patient. Arch Intern Med, 2002; 162:1095–1098.
8.
HaslundP, LeeRA, JemecGB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol, 2009; 89:595–600.
9.
BrunassoAM, MassoneC. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab. Acta Derm Venereol, 2011; 91:70–71.
10.
AlecsandruD, PadillaB, IzquierdoJA, Fernández-CruzE, Sánchez-RamónS. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol, 2010; 146:1343–1345.
11.
XuLY, WrightDR, MahmoudBH, OzogDM, MehreganDA, HamzaviIH. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. Arch Dermatol, 2011; 147:21–28.
